Accudial Pharmaceutical
Boca Raton
About Accudial Pharmaceutical
AccuDial Pharmaceutical is comprised of two business units, which are AccuDial Pharmaceutical and Spinformation. AccuDial Pharmaceutical provides a variety of over-the-counter (OTC) and nutraceutical products for children and adults in liquid and pill form. The combined worldwide, total, addressable market for the AccuDial Pharmaceutical business units is approximately $3 billion. The Company utilizes its patented Spinformation label technology to differentiate AccuDial products from national and store brand manufacturers. Spinformation, established in 2000 by Stephen Key, developed and patented the Expanded Content Rotating Label technology. Spinformation increases the amount of printable space on a label of up to 75%. The technology is well suited for cosmetic, food, beverage, pharmaceutical, nutraceutical, and health and beauty markets. The labels can be applied to almost any bottle design and are useful for mail-in rebates, recipes, instant redeemable coupons, multiple language translations, and drug or nutrition facts. The labels can be printed with four-color process graphics. Although the company is privately owned it operates, discloses, and reports to its Shareholders as if it were a listed company.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $12.4M
- Last round: Debt Financing (Nov 2014)
- Website: accudialpharmaceutical.com
- Phone: 561-429-6886
Industries & Categories
Biotechnology, Health Care, Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/accudial-pharmaceutical-3081889 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.